Skip to main content

Table 1 Characteristic of randomized controlled trials included

From: Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials

Reference phase Country Asthma severity Patients(n) dupilumab/placebo Treatment
duration
Follow up Dosage Outcomes
Wenzel 2013 [27] 2A The US Moderate-to-severe;
blood eosinophil count of at least 300 cells/μl
52/52 12 weeks 8 weeks 300 mg q1w FEV1; PEF; ACQ5 score; FENO;
Asthma exacerbations;
Morning and evening asthma score
Wenzel 2016 [15] 2b Multinational Uncontrolled moderate-to-severe asthma 611/158 24 weeks 12 weeks 200 mg q4w
300 mg q4w
200 mg q2w
300 mg q2w
FEV1; ACQ5 score; FENO; AQLQ;
Severe asthma exacerbations;
Morning and evening asthma score
Castro 2018 [26] 3 Multinational Uncontrolled moderate-to-severe asthma Group 1: 631/313
Group 2: 632/321
52 weeks 12 weeks 200 mg q2w
300 mg q2w
FEV1; PEF; ACQ5 score; FENO;
AQLQ; Severe asthma exacerba-tions;
Morning and evening asthma score
Rabe 2018 [25] 3 Multinational Oral glucocorticoid–dependent severe asthma 103/107 24 weeks NM 300 mg q2w FEV1; FENO;
Severe asthma exacerbations Reduction in the oral glucocorticoid dose
Weinstein 2018 [24] 2b Multinational Uncontrolled persistent asthma Group 1: 92/56
Group 2: 157/84
24 weeks NM 200 mg q2w
300 mg q2w
FEV1;
Severe asthma exacerbations
  1. Abbreviations: FEV1 forced expiratory volume in 1 s, PEF peak expiratory flow, ACQ-5 5-item Asthma Control Questionnaire, FENO fractional exhaled nitric oxide, AQLQ the Asthma Quality of Life Questionnaire, NM not mentioned, q1w once weekly, q2w every 2 weeks, q4w every 4 weeks